Welcome to our dedicated page for Corcept Therapeutics SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Corcept Therapeutics Inc. (CORT) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI-powered summaries that help explain their contents. Corcept is a Nasdaq-listed, commercial-stage pharmaceutical company focused on cortisol modulation in endocrinologic, oncologic, metabolic and neurologic disorders, and its filings offer detailed insight into this business.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Corcept describes its commercial activities with Korlym, which it identifies as the first FDA-approved medication for patients with endogenous hypercortisolism, as well as its research and development programs in hypercortisolism, solid tumors, ALS and liver disease. These periodic reports typically discuss product revenue, research and development spending, and risks related to drug development and regulation.
Current reports on Form 8-K, some of which are summarized in the data provided, disclose material events such as quarterly financial results, submission and FDA acceptance of New Drug Applications for relacorilant in hypercortisolism and platinum-resistant ovarian cancer, a Marketing Authorization Application to the European Medicines Agency, and the receipt of an FDA Complete Response Letter for relacorilant in hypertension secondary to hypercortisolism. Other 8-K filings describe corporate developments, including changes to distribution agreements for Korlym and board-level changes accompanied by consulting arrangements.
On this page, users can review Corcept’s Forms 10-K, 10-Q and 8-K as they are made available from EDGAR, while AI-generated highlights point out key topics such as clinical trial updates, regulatory milestones, revenue trends and significant contracts. The filings section also surfaces exhibits referenced in 8-Ks, helping investors and researchers understand how Corcept’s cortisol-modulation strategy, pipeline progress and commercial operations are reflected in its official regulatory reporting.
Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff reported an open-market sale of 40,000 shares of Common Stock on May 1, 2026 at a weighted average price of $50.0965 per share. The transaction was executed indirectly through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02, over which he has voting power pursuant to voting agreements.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2024. Following this transaction, the trust holds 2,878,326 shares of Corcept Therapeutics Common Stock, for which Belanoff disclaims beneficial ownership except to the extent of his pecuniary interest.
Corcept Therapeutics Inc. files a Form 144 reporting an intended sale of 20,000 shares of Common Stock through Stifel Nicolaus & Company Inc. on 05/05/2026 via a stock option exercise for cash. The filing also lists three prior dispositions by William Guyer on 03/04/2026, 03/20/2026, and 04/08/2026 totaling 40,000 shares reported with dollar amounts alongside each sale.
Corcept Therapeutics reported a proposed sale of 40,000 shares of Common Stock under Rule 144 via broker Stifel Nicolaus & Company Inc.. The filing also records a prior sale of 26,198 shares on 03/25/2026 for $1,311,825.
Corcept Therapeutics generated Q1 2026 net product revenue of $164.9 million, up modestly year over year, but swung to a net loss of $31.8 million versus prior profit. The loss reflected sharply higher selling, general and administrative costs of $145.4 million and research and development spending of $66.3 million.
The company ended March 31, 2026 with cash, cash equivalents and marketable securities totaling $515.4 million, providing substantial funding for ongoing programs. In March 2026, the FDA approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer, and U.S. sales began in April, adding a new oncology revenue stream alongside Korlym and its authorized generic.
Corcept Therapeutics generated Q1 2026 net product revenue of $164.9 million, up modestly year over year, but swung to a net loss of $31.8 million versus prior profit. The loss reflected sharply higher selling, general and administrative costs of $145.4 million and research and development spending of $66.3 million.
The company ended March 31, 2026 with cash, cash equivalents and marketable securities totaling $515.4 million, providing substantial funding for ongoing programs. In March 2026, the FDA approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer, and U.S. sales began in April, adding a new oncology revenue stream alongside Korlym and its authorized generic.
Corcept Therapeutics reported mixed first-quarter 2026 results, combining strong strategic progress with a temporary loss. Revenue rose to $164.9 million from $157.2 million a year earlier, but higher spending on the Lifyorli launch and Cushing’s growth initiatives pushed operating expenses to $214.5 million, resulting in a net loss of $31.8 million, or $0.30 per diluted share, versus net income of $20.5 million in 2025.
The company ended March 31, 2026 with $515.4 million in cash and investments and increased its 2026 revenue guidance to $950–$1,050 million. The FDA approved Lifyorli (relacorilant) plus nab-paclitaxel for platinum-resistant ovarian cancer in March, and the regimen was added as a preferred option in NCCN Guidelines in April. Corcept also highlighted promising ALS survival data for dazucorilant and expects numerous trial readouts across oncology, Cushing’s syndrome and MASH, while guiding for a return to profitability in the second quarter of 2026.
Corcept Therapeutics reported mixed first-quarter 2026 results, combining strong strategic progress with a temporary loss. Revenue rose to $164.9 million from $157.2 million a year earlier, but higher spending on the Lifyorli launch and Cushing’s growth initiatives pushed operating expenses to $214.5 million, resulting in a net loss of $31.8 million, or $0.30 per diluted share, versus net income of $20.5 million in 2025.
The company ended March 31, 2026 with $515.4 million in cash and investments and increased its 2026 revenue guidance to $950–$1,050 million. The FDA approved Lifyorli (relacorilant) plus nab-paclitaxel for platinum-resistant ovarian cancer in March, and the regimen was added as a preferred option in NCCN Guidelines in April. Corcept also highlighted promising ALS survival data for dazucorilant and expects numerous trial readouts across oncology, Cushing’s syndrome and MASH, while guiding for a return to profitability in the second quarter of 2026.
Corcept Therapeutics director James N. Wilson, through an entity associated with him, reported a bona fide gift of 2,000 shares of Corcept common stock on April 22, 2026. The gift was made by the James N. Wilson and Pamela D. Wilson Trust and is classified under transaction code G, indicating a non-market transfer with no sale proceeds.
After the gift, that trust still held 1,095,532 shares of Corcept common stock indirectly. The filing also lists additional indirect holdings, including 200,000 shares in the Pamela D. Wilson 2025 Grantor Retained Annuity Trust, 200,000 shares in the James N. Wilson 2025 Grantor Retained Annuity Trust, and 901,067 shares held by James and Pamela Wilson Family Partners. A footnote states that Wilson has voting power over certain entities’ shares under voting agreements and disclaims beneficial ownership except to the extent of his pecuniary interest.
CORCEPT THERAPEUTICS INC: INGALLS & SNYDER, LLC amended a Schedule 13G to report beneficial ownership of 7,263,466 shares of Common Stock, representing 6.8% of the class as of 12/31/2025. The filing shows shared dispositive power over all reported shares and no sole voting or dispositive power. The amendment is signed on 04/21/2026.
Corcept Therapeutics is asking stockholders to vote at its May 21, 2026 annual meeting on four main items: electing eight directors, ratifying Ernst & Young as auditor, approving executive pay on an advisory basis and amending the 2024 Incentive Award Plan to add more shares.
The proxy details 107,356,686 common shares outstanding as of April 9, 2026 and shows significant 2025 business progress, including revenue rising from $675.0 million in 2024 to $761.4 million and advancement of relacorilant and other cortisol modulators in oncology and metabolic indications. Executive pay is heavily equity-based, with CEO Joseph Belanoff’s 2025 package including $1.19 million salary, a matching $1.19 million bonus and options valued at about $12.9 million.
Corcept Therapeutics Chief Development Officer William Guyer exercised stock options for 20,000 shares of common stock at an exercise price of $21.65 per share and then sold 20,000 shares. The sale was at a weighted average price of $40.97 per share, with individual trade prices ranging from $40.85 to $41.30.
The transactions occurred on April 7, 2026 and were made under a Rule 10b5-1 trading plan adopted on November 27, 2024. Following the sale, Guyer directly holds 2,231 shares of common stock, including 224 shares underlying restricted stock awards granted on December 1, 2025 and 498 shares underlying restricted stock awards granted on March 2, 2026, which will vest in full on the one-year anniversaries of their grant dates if specified conditions are met. The option exercised was fully exercisable and was scheduled to expire on September 1, 2031.
Corcept Therapeutics director James N. Wilson reported a bona fide gift of 5,000 shares of Common Stock on April 6, 2026. The transfer was made by the James N. Wilson and Pamela D. Wilson Trust and is classified as a non-market, no‑price gift disposition.
Following the gift, the trust held 1,097,532 shares indirectly, while the James and Pamela Wilson Family Partners entity held 901,067 shares, and each of the 2025 Grantor Retained Annuity Trusts held 200,000 shares. Wilson has voting power under voting agreements but disclaims beneficial ownership beyond his pecuniary interest.